Source: International Congress 2016 – Late-breaking topics in airways disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J Mark FitzGerald (Vancouver, Canada), J. Mark FitzGerald, Eugene Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary Ferguson, William Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius, Mitchell Goldman. LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial. Eur Respir J 2016; 48: Suppl. 60, 1969

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 LATE-BREAKING ABSTRACT: Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 LATE-BREAKING ABSTRACT: Multinational, database cohort study to assess severe exacerbation rate in asthma Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Comparison of clinical features of severe persistent asthma and refractory asthma Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Sesonal variations of severe asthma exacerbations in the US Source: International Congress 2014 – Risk factors for respiratory disease Year: 2014 LATE-BREAKING ABSTRACT: The analysis of the severe asthma prevalence rate in China Source: International Congress 2016 – Prevalence of obstructive airway diseases, methods of diagnosis, and lung function testing Year: 2016 Tiotropium for uncontrolled asthma (a meta-analysis) Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Correlation between meteo-climatological factors and asthma exacerbation among children: A prospective study Source: International Congress 2016 – Living with asthma around the globe Year: 2016 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Prevalence of refractory asthma in population with severe asthma Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 LATE-BREAKING ABSTRACT: Disease control rate (DRC) of bronchial asthma during pregnancy Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 LATE-BREAKING ABSTRACT: Vocal cord dysfunction (VCD) in mild and severe asthma Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Childhood obesity in relation to poor asthma control and exacerbations Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016